Appendix cancer other diagnostic studies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
[[Vermiform appendix|Appendix]] [[cancer]] may also be [[Diagnosis|diagnose]]<nowiki/>d using [[scintigraphy]], [[capsule endoscopy]], [[enteroscopy]] | [[Vermiform appendix|Appendix]] [[cancer]] may also be [[Diagnosis|diagnose]]<nowiki/>d using [[scintigraphy]], [[capsule endoscopy]], and [[enteroscopy]]. [[Chromogranin A]] (CgA) and [[5-Hydroxyindoleacetic acid|5-HIAA]] ([[5-Hydroxyindoleacetic acid|5-hydroxyindoleacetic acid]]) are among biochemical markers that might represent level of [[Malignant|malignant cells]] activity in [[carcinoid syndrome]]. | ||
==Other Diagnostic Studies== | ==Other Diagnostic Studies== | ||
* [[Appendix]] cancer may also be [[Diagnosis|diagnose]]<nowiki/>d using the following diagnostic studies:<ref name="pmid17576444">Maroun J, Kocha W, Kvols L, Bjarnason G, Chen E, Germond C et al. (2006) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=17576444 Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.] ''Curr Oncol'' 13 (2):67-76. PMID: [https://pubmed.gov/17576444 17576444]</ref> | * [[Appendix]] cancer may also be [[Diagnosis|diagnose]]<nowiki/>d using the following diagnostic studies:<ref name="pmid17576444">Maroun J, Kocha W, Kvols L, Bjarnason G, Chen E, Germond C et al. (2006) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=17576444 Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.] ''Curr Oncol'' 13 (2):67-76. PMID: [https://pubmed.gov/17576444 17576444]</ref> | ||
| Line 20: | Line 22: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: | [[Category:Surgery]] | ||
[[Category:Medicine]] | |||
[[Category:Emergency medicine]] | |||
[[Category:Oncology]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 18:04, 22 February 2019
|
Appendix cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Appendix cancer other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Appendix cancer other diagnostic studies |
|
Risk calculators and risk factors for Appendix cancer other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Appendix cancer may also be diagnosed using scintigraphy, capsule endoscopy, and enteroscopy. Chromogranin A (CgA) and 5-HIAA (5-hydroxyindoleacetic acid) are among biochemical markers that might represent level of malignant cells activity in carcinoid syndrome.
Other Diagnostic Studies
- The following are among biochemocal markers that might represent level of malignant cells activity in carcinoid syndrome:
- Chromogranin A (CgA)[2]
- 5-HIAA (5-hydroxyindoleacetic acid)[3]
- Ki67: a reliable marker of cell proliferation[4][1]
References
- ↑ 1.0 1.1 Maroun J, Kocha W, Kvols L, Bjarnason G, Chen E, Germond C et al. (2006) Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol 13 (2):67-76. PMID: 17576444
- ↑ Eriksson B, Oberg K, Stridsberg M (2000) Tumor markers in neuroendocrine tumors. Digestion 62 Suppl 1 ():33-8. DOI:10.1159/000051853 PMID: 10940685
- ↑ Oberg K, Janson ET, Eriksson B (1999) Tumour markers in neuroendocrine tumours. Ital J Gastroenterol Hepatol 31 Suppl 2 ():S160-2. PMID: 10604122
- ↑ Oberg K (2003) Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 3 (6):863-77. DOI:10.1586/14737140.3.6.863 PMID: 14686708